Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05188313 | TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer(TRAP-2) | recruiting | Phase 3 | 376 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT04951635 | A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer | recruiting | Phase 3 | 150 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| Jun 16, 2022 |
| clinicaltrials |
| NCT03829553 | Hypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment(HARVEST) | recruiting | Phase 3 | 801 | Ruijin HospitalOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT04807673 | Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)(KEYSTONE-002) | recruiting | Phase 3 | 342 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT04079049 | BreCLIM-2 - A RCT Investigating Local Treatment for Breast Cancer Liver Metastases(BreCLIM-2) | recruiting | Phase 3 | 200 | Umeå UniversityOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT03824275 | 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer | active not recruiting | Phase 2 / Phase 3 | 129 | Columbia UniversityOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT04437329 | Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 352 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05367206 | Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial(N6C) | recruiting | Phase 3 | 280 | Sun Yat-sen UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05342792 | Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma | recruiting | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05230771 | Clinical Outcome of Palliative Surgery After Translational Therapy for Metastatic Gastric Cancer Versus Maintenance Chemotherapy for Metastatic Gastric Cancer | not yet recruiting | Phase 3 | 120 | Fujian Medical UniversityOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT05253170 | Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients | not yet recruiting | Phase 3 | 622 | Seoul National University Bundang HospitalOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT05270824 | Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma | not yet recruiting | Phase 3 | 120 | Fujian Medical UniversityOTHER | 0 | Mar 8, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT05201430 | Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer(RCNAC) | recruiting | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05044117 | Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN) | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT04762459 | Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection(APEX) | enrolling by invitation | Phase 3 | 606 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT04787354 | Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX) | recruiting | Phase 3 | 976 | Hallym University Medical CenterOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT04947059 | Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)(GENSA) | recruiting | Phase 3 | 180 | University of ThessalyOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT04974346 | Para-aortic Prophylactic Irradiation for Locally Advanced Cervical Cancer(PAILACC) | recruiting | Phase 3 | 455 | Zhejiang Cancer HospitalOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT05194878 | Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers | recruiting | Phase 3 | 840 | Sun Yat-sen UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT05172518 | Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer | not yet recruiting | Phase 3 | 512 | Sun Yat-sen UniversityOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT02535221 | Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer | recruiting | Phase 3 | 234 | Peking UniversityOTHER | 1 | Nov 29, 2021 | clinicaltrials |
| NCT04969731 | Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | recruiting | Phase 3 | 408 | GC Cell CorporationINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04009265 | Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma | recruiting | Phase 3 | 819 | Fujian Medical University Union HospitalOTHER | 1 | Nov 12, 2021 | clinicaltrials |
| NCT04595864 | Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation | recruiting | Phase 3 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT04316364 | A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC | recruiting | Phase 3 | 537 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05059379 | Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer(SUCLANODE) | recruiting | Phase 3 | 1,650 | Fudan UniversityOTHER | 1 | Oct 25, 2021 | clinicaltrials |
| NCT05086614 | Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer | recruiting | Phase 3 | 2,500 | Fudan UniversityOTHER | 1 | Oct 21, 2021 | clinicaltrials |
| NCT05080010 | Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma | recruiting | Phase 3 | 500 | Sun Yat-sen UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT04670029 | Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line(PHARAOM) | recruiting | Phase 3 | 186 | WepromOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT05062005 | ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 3 | 447 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT03463252 | Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC | recruiting | Phase 2 / Phase 3 | 224 | West China Second University HospitalOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT04997837 | Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma | recruiting | Phase 3 | 433 | Fudan UniversityOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT04973319 | Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy | not yet recruiting | Phase 3 | 450 | Shengjing HospitalOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04137653 | Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT | recruiting | Phase 3 | 1,498 | Shengjing HospitalOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04376866 | Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 204 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT04384601 | Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer | not yet recruiting | Phase 3 | 246 | Ruijin HospitalOTHER | 1 | Jul 19, 2021 | clinicaltrials |
| NCT04890522 | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC | not yet recruiting | Phase 2 / Phase 3 | 622 | Sun Yat-sen UniversityOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT04829708 | Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy | recruiting | Phase 3 | 534 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT04799002 | Topotecan and Melphalan for Retinoblastoma | recruiting | Phase 3 | 50 | Sun Yat-sen UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT04778956 | Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma | recruiting | Phase 3 | 218 | Sun Yat-sen UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04772287 | Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) | not yet recruiting | Phase 3 | 341 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Feb 26, 2021 | clinicaltrials |
| NCT04215510 | Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT | not yet recruiting | Phase 3 | 286 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04736589 | Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway | not yet recruiting | Phase 3 | 270 | Peking Union Medical CollegeOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04733820 | Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery | recruiting | Phase 3 | 340 | Huazhong University of Science and TechnologyOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT04483076 | Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer(RESONANCE-II) | recruiting | Phase 3 | 524 | Chinese PLA General HospitalOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04677673 | Neoadjuvant Chemotherapy Plus Surgery Versus Surgery First For Elderly Gastric Cancer Patients(RJGC-Senile) | not yet recruiting | Phase 2 / Phase 3 | 232 | BIRENDRA KUMAR SAHOTHER | 0 | Dec 21, 2020 | clinicaltrials |
| NCT04646759 | Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer | recruiting | Phase 3 | 516 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 30, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Jun 24, 2022source: clinicaltrials